XOMA EXPANDS BCE TECHNOLOGY LICENSE WITH CRUCELL

XOMA Ltd. (Nasdaq:XOMA) today announced that it has expanded its existing non-exclusive, worldwide license to Crucell N.V. (Euronext, Nasdaq: CRXL) under XOMA's bacterial cell expression (BCE) technology to improve Crucell's position to perform phage display in the field of infectious disease with third party collaborators. Details of the license fee and future milestone and royalty payments to XOMA were not disclosed.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1071978XSL_NEWSML_TO_NEWSML_WEB.xml)